Fresenius Medical Care AG & Co. KGaA

FMS

NYSE

22.83

USD

-0.42(-1.81%)

As of today

Overview Financials Dividends Ratios Discussions Analysis

Fresenius Medical Care AG & Co. KGaA fundamentals

Overview Income Statement Balance Sheet Cash Flow

Key ratios

P/E Ratio

16.08

Price/Book

0.87

Debt/Equity

83.07%

Return on Equity

4.70%

Dividend Yield

3.45%

EBITDA

3.21B

Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, it operated 4,171 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.

Statements Highlights

AnnualQuarterly

Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024
Total Revenue	17,859,063,000	17,618,685,000	19,398,017,000	19,453,617,000	19,335,909,000
Gross Profit	5,537,445,000	4,773,029,000	4,893,689,000	4,925,005,000	4,756,652,000
Operating Income	2,304,409,000	1,852,290,000	1,511,755,000	1,369,438,000	1,392,395,000
Net Income	1,164,377,000	969,308,000	673,405,000	498,997,000	537,913,000
Total Assets	31,689,036,000	34,366,558,000	35,754,114,000	33,929,808,000	33,566,579,000
Total Current Liabilities	6,056,235,000	7,257,634,000	6,467,314,000	6,111,590,000	5,660,060,000
Total Equity	12,331,310,000	13,979,037,000	15,449,179,000	14,826,535,000	15,768,513,000
Free Cash Flow	3,181,173,000	1,635,138,000	1,443,391,000	1,944,205,000	1,686,786,000
Cash from Operations	4,233,156,000	2,489,498,000	2,167,379,000	2,628,801,000	2,386,144,000
Cash from Investing	-1,334,942,000	-1,196,228,000	-734,725,000	-544,227,000	-84,939,000
Cash from Financing	-2,664,027,000	-1,024,382,000	-1,617,360,000	-1,858,529,000	-2,569,300,000
Net Change in Cash	73,816,000	400,116,000	-207,868,000	153,438,000	-241,897,000

Fresenius Medical Care AG & Co. KGaA

FMS

22.83

Fresenius Medical Care AG & Co. KGaA fundamentals

Key ratios

Statements Highlights

Dividends

Analyst Recomendations